Drug intelligence / Profile preview

MT-6345

Development stage: Phase 1
Lead developer: Mitsubishi Tanabe Pharma
Modality: Small Molecules
Administration: Oral

Overview

MT-6345 is a small molecule drug that was developed by Mitsubishi Tanabe Pharma for the treatment of nervous system diseases, with a primary focus on binge eating disorder (BED). The drug entered Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy subjects. However, development was discontinued after Phase 1. The precise mechanism of action for MT-6345 has not been disclosed or remains unknown[1][2][3][4][5].

Beyond the preview

Go deeper on MT-6345.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT-6345.

Explore the full profile